{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:00:18Z","timestamp":1777500018879,"version":"3.51.4"},"reference-count":88,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1002\/jps.24560","type":"journal-article","created":{"date-parts":[[2015,7,6]],"date-time":"2015-07-06T18:22:54Z","timestamp":1436206974000},"page":"3289-3298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Nifedipine"],"prefix":"10.1016","volume":"104","author":[{"given":"Jayachandar","family":"Gajendran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinod P.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Langguth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Polli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehul","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.W.","family":"Groot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"Cristofoletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertil","family":"Abrahamsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer B.","family":"Dressman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1002\/jps.24560_bb0005","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/jps.20131","article-title":"Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: Verapamil hydrochloride, propranolol hydrochloride, and atenolol","volume":"93","author":"Vogelpoel","year":"2004","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.24560_bb0010","unstructured":"WHO. 2013. Model list of essential medicines (18th). Accessed (03\/16\/2015) at: http:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/18th EML Final web 8Jul13.pdf."},{"key":"10.1002\/jps.24560_bb0015","series-title":"Clarke\u2019s analysis of drugs and poisons","first-page":"1337","year":"2004"},{"issue":"6","key":"10.1002\/jps.24560_bb0020","first-page":"389","article-title":"Nifedipin: Monographie zur Prufung der Bioverf\u00fcgbarkeit\/Bio\u00e4quivalenz von schnell-freisetzenden Zubereitungen","volume":"133","author":"Blume","year":"1988","journal-title":"Pharm Ztg"},{"key":"10.1002\/jps.24560_bb0025","unstructured":"Martindale. The extra pharmacopoeia. 31st ed. London, UK: Royal Pharmaceutical Society."},{"issue":"6B","key":"10.1002\/jps.24560_bb0030","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0002-9343(87)90630-9","article-title":"Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. A controlled-release formulation of nifedipine","volume":"83","author":"Chung","year":"1987","journal-title":"Am J Med"},{"issue":"4","key":"10.1002\/jps.24560_bb0035","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/j.1552-4604.1983.tb02720.x","article-title":"Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects","volume":"23","author":"Foster","year":"1983","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1002\/jps.24560_bb0040","first-page":"256","article-title":"Pharmacokinetics and bioavailability of three different galenic nifedipine preparations","volume":"36","author":"Pabst","year":"1986","journal-title":"Arzneimittelforschung"},{"issue":"6","key":"10.1002\/jps.24560_bb0045","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/clpt.1984.105","article-title":"Nifedipine: Kinetics and dynamics in healthy subjects","volume":"35","author":"Kleinbloesem","year":"1984","journal-title":"Clin Pharmacol Ther"},{"issue":"4 Pt 2","key":"10.1002\/jps.24560_bb0050","first-page":"II29","article-title":"Pharmacokinetic studies of nifedipine tablet. Correlation with antihypertensive effects","volume":"5","author":"Taburet","year":"1983","journal-title":"Hypertension"},{"key":"10.1002\/jps.24560_bb0055","series-title":"Bunderverband der Pharmazeutischen Industrie, Editio Cantor Verlag fuer Medizin und Naturwissenschaften","author":"Liste","year":"2013"},{"issue":"6","key":"10.1002\/jps.24560_bb0060","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/BF00608223","article-title":"Dose response and length of action of nifedipine capsules and tablets in patients with essential hypertension: A randomised crossover study","volume":"30","author":"Cappuccio","year":"1986","journal-title":"Eur J Clin Pharmacol"},{"issue":"Suppl 6A","key":"10.1002\/jps.24560_bb0065","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/0002-9343(86)90787-4","article-title":"Kinetics and dynamics of nifedipine after oral and sublingual doses","volume":"81","author":"McAllister","year":"1986","journal-title":"Am J Med"},{"issue":"12","key":"10.1002\/jps.24560_bb0070","first-page":"1434","article-title":"Effect of slow release nifedipine tablets in patients with essential hypertension","volume":"42","author":"Imai","year":"1992","journal-title":"Arzneimittelforschung"},{"issue":"6","key":"10.1002\/jps.24560_bb0075","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/0002-9149(80)90366-5","article-title":"Comparative pharmacology of calcium antagonists: Nifedipine, verapamil and diltiazem","volume":"46","author":"Henry","year":"1980","journal-title":"Am J Cardiol"},{"key":"10.1002\/jps.24560_bb0080","series-title":"Clinical pharmacology","first-page":"130","article-title":"Treatment of cardiovascular diseases by Adalat (nifedipine)","author":"Kuhlmann","year":"1986"},{"key":"10.1002\/jps.24560_bb0085","first-page":"55","article-title":"Zur pharmakokinetik. von nifedipin","volume":"4","author":"Raemsch","year":"1981","journal-title":"Schwerpunkt Med"},{"key":"10.1002\/jps.24560_bb0090","series-title":"Interpretation of diagnostic tests","first-page":"1098","article-title":"Therapeutic drug monitoring and drug effects","author":"Raemsch","year":"2006"},{"issue":"6","key":"10.1002\/jps.24560_bb0095","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.2042-7158.1986.tb04619.x","article-title":"Accumulation of nifedipine after multiple doses","volume":"38","author":"Lesko","year":"1986","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"10.1002\/jps.24560_bb0100","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0040-6031(02)00221-6","article-title":"Investigation of the polymorphic transformations from glassy nifedipine","volume":"397","author":"Keymolen","year":"2003","journal-title":"Thermochim Acta"},{"key":"10.1002\/jps.24560_bb0105","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/clinchem\/29.1.158","article-title":"Measurement of nifedipine in plasma by gas-liquid chromatography and electron-capture detection","volume":"29","author":"Hamann","year":"1983","journal-title":"Clin Chem"},{"key":"10.1002\/jps.24560_bb0110","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0039-9140(89)80201-2","article-title":"Nifedipine: Differential pulse polarography and photodecomposition","volume":"36","author":"Squella","year":"1989","journal-title":"Talanta"},{"issue":"2","key":"10.1002\/jps.24560_bb0115","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0378-4347(00)84047-5","article-title":"Determination of nifedipine in human plasma by high-performance liquid chromatography with electrochemical detection","volume":"341","author":"Suzuki","year":"1985","journal-title":"J Chrom B"},{"issue":"1","key":"10.1002\/jps.24560_bb0120","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0378-4347(00)82066-6","article-title":"Gas chromatographic determination of nifedipine and one of its metabolites using electron capture detection","volume":"162","author":"Jakobsen","year":"1979","journal-title":"J Chrom B"},{"key":"10.1002\/jps.24560_bb0125","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1021\/ja01607a067","article-title":"Dihydropyridines. II. The photochemical disproportionation of 4-(2-nitrophenyl)-1,4-dihydropyridines","volume":"77","author":"Berson","year":"1955","journal-title":"J Am Chem Soc"},{"key":"10.1002\/jps.24560_bb0130","unstructured":"European Pharmacopoeia. 2010. Nifedipine. 7th ed. Strasbourg, France, pp 2571\u20132572."},{"issue":"9","key":"10.1002\/jps.24560_bb0135","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1002\/jps.23611","article-title":"Utilizing in vitro and PBPK tools to link ADME characteristics to plasma profiles: case example nifedipine immediate release formulation","volume":"102","author":"Wagner","year":"2013","journal-title":"J Pharm Sci"},{"issue":"10","key":"10.1002\/jps.24560_bb0140","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1023\/A:1015979021590","article-title":"Complexation of nifedipine with substituted phenolic ligands","volume":"5","author":"Boje","year":"1988","journal-title":"Pharm Res"},{"key":"10.1002\/jps.24560_bb0145","series-title":"Nifedipine","article-title":"Analytical Profiles of Drug Substances","author":"Ali","year":"1989"},{"issue":"2","key":"10.1002\/jps.24560_bb0150","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0378-5173(97)00282-2","article-title":"Solubility and in vitro transdermal permeation of nifedipine","volume":"159","author":"Squillante","year":"1997","journal-title":"Int J Pharm"},{"issue":"4","key":"10.1002\/jps.24560_bb0155","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/08037050152669738","article-title":"Comparison of the time courses and potencies of the vasodilator effects of nifedipine and felodipine in the human forearm","volume":"10","author":"van der Lee","year":"2001","journal-title":"Blood Press"},{"key":"10.1002\/jps.24560_bb0160","series-title":"Adalat: A comprehensive review","first-page":"1","author":"Lichtlen","year":"1991"},{"key":"10.1002\/jps.24560_bb0165","first-page":"407","article-title":"The importance of drug ionization for the action of calcium-antagonists and related compounds","volume":"34","author":"Mannhold","year":"1984","journal-title":"Arzneimittelforschung"},{"key":"10.1002\/jps.24560_bb0170","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1021\/mp060042f","article-title":"The suitability of an in situ perfusion model for permeability determinations: Utility for BCS class I biowaiver requests","volume":"3","author":"Kim","year":"2006","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1002\/jps.24560_bb0175","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s002280050092","article-title":"Investigation of nifedipine absorption in different regions of the human gastrointestinal (GI) tract after simultaneous administration of 13C- and 12C-nifedipine","volume":"50","author":"Bode","year":"1996","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1002\/jps.24560_bb0180","first-page":"73","article-title":"Clinical and pharmacokinetic comparison of 2 oral preparations ofnifedipine: 10mg capsules and 20mg delayed-release tablets","volume":"59","author":"Vidal-Garate","year":"1989","journal-title":"Arch Inst Cardiol Mex"},{"issue":"4 Pt 2","key":"10.1002\/jps.24560_bb0185","first-page":"II18","article-title":"Pharmacokinetics and metabolism of nifedipine","volume":"5","author":"Raemsch","year":"1983","journal-title":"Hypertension"},{"key":"10.1002\/jps.24560_bb0190","series-title":"International adalat symbosium","first-page":"33","article-title":"Pharmacokinetics of nifedipine-14C in man","author":"Horster","year":"1975"},{"issue":"2","key":"10.1002\/jps.24560_bb0195","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/bdd.2510050204","article-title":"Bioavailability of nifedipine: A comparison between two preparations","volume":"5","author":"Zylber-Katz","year":"1984","journal-title":"Biopharm Drug Dispos"},{"issue":"12","key":"10.1002\/jps.24560_bb0200","first-page":"1597","article-title":"The bioequivalence of two nifedipine fluid capsules","volume":"39","author":"Thurmann","year":"1989","journal-title":"Arzneimittelforschung"},{"key":"10.1002\/jps.24560_bb0205","first-page":"2849","article-title":"Bioverfugbarkeit einer neuen nifedipin-weichgelatine-kapseln","volume":"35","author":"Gikalov","year":"1985","journal-title":"Therapiewoche"},{"issue":"2","key":"10.1002\/jps.24560_bb0210","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00613808","article-title":"Acute antihypertensive effect and pharmacokinetics of a tablet preparation of nifedipine","volume":"24","author":"Banzet","year":"1983","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"10.1002\/jps.24560_bb0215","first-page":"1266","article-title":"Study on the bioequivalence of an oral nifedipine formulation and a sustained release reference preparation after single dose and repeated doses","volume":"45","author":"Troger","year":"1995","journal-title":"Arzneimittelforschung"},{"issue":"9","key":"10.1002\/jps.24560_bb0220","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0090-9556(24)02976-3","article-title":"Evaluation of a novel in vitro Caco-2 hepatocyte hybrid system for predicting in vivo oral bioavailability","volume":"32","author":"Lau","year":"2004","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1002\/jps.24560_bb0225","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1021\/mp034006h","article-title":"Molecular properties of WHO essential drugs and provisional biopharmaceutical classification","volume":"1","author":"Kasim","year":"2004","journal-title":"Mol Pharm"},{"issue":"4","key":"10.1002\/jps.24560_bb0230","first-page":"455","article-title":"The binding of 4-(2\u2032-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester (nifedipine) as well as other coronary active substances to serum albumins","volume":"24","author":"Rosenkranz","year":"1974","journal-title":"Arzneimittelforschung"},{"key":"10.1002\/jps.24560_bb0235","first-page":"330","article-title":"Klinische Untersuchungen zur pharmakokinetik von radioaktiv markiertem 4-(2'-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridin-3,5-dicarbonsauredimethylester","volume":"22","author":"Horster","year":"1972","journal-title":"Arzneimit-telforschung"},{"issue":"6","key":"10.1002\/jps.24560_bb0240","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1365-2125.1984.tb02569.x","article-title":"The first pass metabolism of nifedipine in man","volume":"18","author":"Waller","year":"1984","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1002\/jps.24560_bb0245","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/clpt.1987.110","article-title":"Effect of food on nifedipine pharmacokinetics","volume":"42","author":"Reitberg","year":"1987","journal-title":"Clin Pharmacol Ther"},{"key":"10.1002\/jps.24560_bb0250","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). 2002. Guidance for industry: Food-effect bioavailability and fed bioequivalence studies. http:\/\/www.fda.gov\/downloads\/ RegulatoryInformation\/Guidances\/UCM126833.pdf."},{"issue":"1","key":"10.1002\/jps.24560_bb0255","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF00635716","article-title":"Effect of food ingestion on nifedipine absorption and haemodynamic response","volume":"28","author":"Hirasawa","year":"1985","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"10.1002\/jps.24560_bb0260","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1248\/yakushi.122.323","article-title":"Effect of grapefruit pulp on the pharmacokinetics of the dihydropyridine calcium antagonists nifedipine and nisoldipine","volume":"122","author":"Ohtani","year":"2002","journal-title":"Yakugaku Zasshi J Pharm Soc Jpn"},{"issue":"1","key":"10.1002\/jps.24560_bb0265","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2125.1995.tb04534.x","article-title":"Factors affecting the absolute bioavailability of nifedipine","volume":"40","author":"Rashid","year":"1995","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1002\/jps.24560_bb0270","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2710.2004.00618.x","article-title":"Grapefruit juice-nifedipine interaction: Possible involvement of several mechanisms","volume":"30","author":"Odou","year":"2005","journal-title":"J Clin Pharm Ther"},{"issue":"10","key":"10.1002\/jps.24560_bb0275","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0090-9556(25)08415-6","article-title":"The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism","volume":"24","author":"Holtbecker","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"10.1002\/jps.24560_bb0280","article-title":"Bio\u00e4quivalenz: Qualit\u00e4tsbewertung wirkstoffgleicher Fertigarzneimittel","volume":"3\u201312","author":"Blume","year":"1989","journal-title":"Frankfurt am Main. GoviVerlag"},{"key":"10.1002\/jps.24560_bb0285","series-title":"Bunderverband der Pharmazeutischen Industrie, Editio Cantor Verlag fuer Medizin und Naturwissenschaften","author":"Liste","year":"1992"},{"key":"10.1002\/jps.24560_bb0290","series-title":"Bunderverband der Pharmazeutischen Industrie, Editio Cantor Verlag fuer Medizin und Naturwissenschaften","author":"Liste","year":"2002"},{"key":"10.1002\/jps.24560_bb0295","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0928-0987(93)90007-W","article-title":"Report of consensus meeting: Biointernational \u201892. Conference on bioavailability, bioequivalence and pharmacokinetic studies","volume":"1","author":"Blume","year":"1993","journal-title":"Eur J Pharm Sci"},{"key":"10.1002\/jps.24560_bb0300","first-page":"308","article-title":"Monographie zur Pr\u00fcfung der Bioverf\u00fcgbarkeit\/Bio\u00e4quivalenz von schnell-freisetzenden Zubereitungen [1]","volume":"6","author":"Blume","year":"1988","journal-title":"Deutsche Apotheker Zeitung"},{"key":"10.1002\/jps.24560_bb0305","unstructured":"European Medicines Agency (EMA). 2001. Committee for proprietary medicinal products (CPMP). Note for guidance on the investigation of bioavailability and bioequivalence. http:\/\/www.emea. europa.eu\/pdfs\/human\/ewp\/140198en.pdf."},{"key":"10.1002\/jps.24560_bb0310","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). 2014. Guidance for industry: Bioavailability and bioequivalence studies submitted in NDAs or INDs\u2014General considerations. http:\/\/www.fda.gov\/downloads\/drugs\/ guidancecomplianceregulatoryinformation\/guidances\/ucm389370.pdf."},{"key":"10.1002\/jps.24560_bb0315","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). 2001. Guidance for industry: Statistical approaches to establishing bioequivalence. http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/ucm070244.pdf."},{"issue":"12","key":"10.1002\/jps.24560_bb0320","first-page":"1842","article-title":"Bioavailability of new nifedipine preparations in man. 2. Bioequivalence of nifedipine in the form of soft gelatin capsules","volume":"35","author":"Dahmen","year":"1985","journal-title":"Arzneimittelforschung"},{"issue":"1","key":"10.1002\/jps.24560_bb0325","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/bdd.2510080104","article-title":"The bioavailability of oral nifedipine formulations: A statistical and simulation approach","volume":"8","author":"Kozjek","year":"1987","journal-title":"Biopharm Drug Dispos"},{"issue":"11","key":"10.1002\/jps.24560_bb0330","first-page":"1296","article-title":"Biotransformation and bioequivalence of a new nifedipine preparation","volume":"37","author":"Achtert","year":"1987","journal-title":"Arzneimittelforschung"},{"issue":"3","key":"10.1002\/jps.24560_bb0335","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/BF03189816","article-title":"Comparative pharmacokinetics of two nifedipine products in capsule form following single oral administration in healthy volunteers","volume":"22","author":"Rawashdeh","year":"1997","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"2","key":"10.1002\/jps.24560_bb0340","first-page":"300","article-title":"A model study of bioequivalence of dissolved nifedipine from soft gelatin capsules","volume":"38","author":"Menke","year":"1988","journal-title":"Arzneimittelforschung"},{"issue":"9","key":"10.1002\/jps.24560_bb0345","first-page":"337","article-title":"Pharmacokinetics and pharmacodynamics of two commercial oral nifedipine products","volume":"29","author":"Shaheen","year":"1991","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"10.1002\/jps.24560_bb0350","unstructured":"United States Pharmacopeia (USP 30-NF 25), United States Pharmacopeial Convention, Inc., Rockville, Maryland."},{"key":"10.1002\/jps.24560_bb0355","unstructured":"WHO. 2006. Proposal to waive in vivo bioequivalence requirements for WHO model list of essential medicines immediate-release, solid oral dosage forms. Technical Report Series, No 937, 40th Report, Annex 8 of WHO Expert committee on specifications for pharmaceutical preparations. Accessed, at: http:\/\/healthtechwhoint\/pq\/info-general\/documents\/TRS937\/WHO-TRS-937__annex8-eng.pdf."},{"issue":"4","key":"10.1002\/jps.24560_bb0360","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2710.1995.tb00656.x","article-title":"In vitro dissolution studies on nifedipine capsules","volume":"20","author":"Mehta","year":"1995","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"10.1002\/jps.24560_bb0365","first-page":"55","article-title":"Pharmaceutical quality of nifedipine soft capsules commercially available in Thailand","volume":"11","author":"Akarawut","year":"2002","journal-title":"J Health Sci"},{"key":"10.1002\/jps.24560_bb0370","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). 2000. Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms based on a biopharmaceutics classification system. http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/ucm070246.pdf."},{"key":"10.1002\/jps.24560_bb0375","unstructured":"The European Agency for the Evaluation of Medicinal Products (EMEA), Committee for Proprietary Medicinal Products (CPMP). 2001. Note for guidance on the investigation of bioavailability and bioequivalence. http:\/\/www.ema.europa.eu\/docs\/en-GB\/ document-library\/Scientific-guideline\/2009\/09\/WC500003519.pdf."},{"key":"10.1002\/jps.24560_bb0380","unstructured":"World Health Organization (WHO). 2006. Proposal to waive in vivo bioequivalence requirements for WHO model list of essential medicines immediate-release, solid oral dosage forms. Accessed (03\/16\/2015) at: http:\/\/www.who.int\/medicines\/services\/expertcommittees\/pharmprep\/QAS04-093Rev4-final.pdf."},{"key":"10.1002\/jps.24560_bb0385","series-title":"Essential medicines WHO Model List (EML)","author":"World Health Organization (WHO)","year":"2013"},{"key":"10.1002\/jps.24560_bb0390","series-title":"Analytical profiles of drug substances: Nifedipine. Analytical profiles of drug substances","first-page":"230","author":"Syed","year":"1989"},{"issue":"2","key":"10.1002\/jps.24560_bb0395","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejpb.2004.03.001","article-title":"Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system","volume":"58","author":"Lindenberg","year":"2004","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1002\/jps.24560_bb0400","unstructured":"United States Pharmacopeia (USP 37-NF 32), United States Pharmacopeial Convention, Inc., Rockville, Maryland."},{"issue":"9","key":"10.1002\/jps.24560_bb0405","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1021\/js960263k","article-title":"Dissolution testing of soft shell capsules\u2014Acetaminophen and nifedipine","volume":"86","author":"Bottom","year":"1997","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1002\/jps.24560_bb0410","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1002\/jps.22026","article-title":"Analysis of nifedipine absorption from soft gelatin capsules using PBPK modeling and biorelevant dissolution testing","volume":"99","author":"Thelen","year":"2010","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1002\/jps.24560_bb0415","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejpb.2006.08.007","article-title":"Effect of poloxamers on nifedipine microparticles prepared by hot air coating technique","volume":"65","author":"Pattarino","year":"2007","journal-title":"Eur J Pharm Biopharm"},{"issue":"7","key":"10.1002\/jps.24560_bb0420","first-page":"595","article-title":"Increased dissolution and physical stability of micronized nifedipine particles encapsulated with a biocompatible polymer and surfactants in a wet ball milling process","volume":"61","author":"Li","year":"2006","journal-title":"Pharmazie"},{"issue":"5","key":"10.1002\/jps.24560_bb0425","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1248\/yakushi1947.104.5_485","article-title":"Solid dispersion obtained from nifedipine and enteric coating agents. I. Dissolution behavior","volume":"104","author":"Hasegawa","year":"1984","journal-title":"Yakugaku Zasshi J Pharm Soc Jpn"},{"issue":"8","key":"10.1002\/jps.24560_bb0430","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1080\/03639040500216097","article-title":"Solid state and dissolution rate characterization of co-ground mixtures of nifedipine and hydrophilic carriers","volume":"31","author":"Friedrich","year":"2005","journal-title":"Drug Dev Ind Pharm"},{"issue":"7","key":"10.1002\/jps.24560_bb0435","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1081\/DDC-120005625","article-title":"Improving the dissolution and bioavailability of nifedipine using solid dispersions and solubilizers","volume":"28","author":"Emara","year":"2002","journal-title":"Drug Dev Ind Pharm"},{"issue":"1\u20132","key":"10.1002\/jps.24560_bb0440","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijpharm.2005.05.014","article-title":"Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine","volume":"299","author":"Hecq","year":"2005","journal-title":"Int J Pharm"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916301149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916301149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:23:18Z","timestamp":1758360198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354916301149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":88,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0022354916301149"],"URL":"https:\/\/doi.org\/10.1002\/jps.24560","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Nifedipine","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1002\/jps.24560","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Wiley Periodicals, Inc. and the American Pharmacists Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}